SCHEMBL874302

SCHEMBL874302

COc1ccc(OC(C)=O)cc1F

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.54
HTT P42858 2/20 0.54
MAPK1 P28482 1/20 0.54
RAB9A P51151 1/20 0.54
SMN1; SMN2 Q16637 1/20 0.49
TUBB4A P04350 2/20 0.49
TUBB P07437 2/20 0.49
TUBA3C P0DPH7 2/20 0.49
TUBA1B P68363 2/20 0.49
TUBA4A P68366 2/20 0.49
TUBB4B P68371 2/20 0.49
TUBB3 Q13509 2/20 0.49
TUBB2A Q13885 2/20 0.49
TUBB8 Q3ZCM7 2/20 0.49
TUBA3E Q6PEY2 2/20 0.49
TUBA1A Q71U36 2/20 0.49
TUBA1C Q9BQE3 2/20 0.49
TUBB6 Q9BUF5 2/20 0.49
TUBB2B Q9BVA1 2/20 0.49
TUBB1 Q9H4B7 2/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28782473 0.86 BACE1 (0.56) LMNAHTTMAPK1RAB9ASMN1; SMN2
SCHEMBL3234553 0.86 KDM4E (0.53) LMNAMAPK1TUBB4ATUBBTUBA3C
SCHEMBL29019507 0.83 LMNA (0.49) LMNAHTTMAPK1RAB9ATUBB1
SCHEMBL153056 0.83 CA12 (0.59) LMNAMAPK1TUBB4ATUBBTUBA3C
SCHEMBL2729632 0.81 TSHR (0.64) MAPK1RAB9ASMN1; SMN2TUBB4ATUBB
SCHEMBL3236668 0.81 KDM4E (0.46) LMNAHTTRAB9AKDM4EMEN1
SCHEMBL28365704 0.81 LMNA (0.50) LMNAHTTMAPK1RAB9ASMN1; SMN2
SCHEMBL31621879 0.81 LMNA (0.52) LMNAMAPK1SMN1; SMN2KDM4EMEN1
SCHEMBL823757 0.81 LMNA (0.52) LMNAMAPK1SMN1; SMN2KDM4EMEN1
SCHEMBL14451171 0.80 KMT2A (0.60) LMNAHTTMAPK1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 105 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-108368090-A Compounds as Immunomodulators 百时美施贵宝公司 2018-08-03 CN claimed
CN-106714770-A Hydroxysteroid compounds, intermediates thereof, preparation method, composition and uses thereof 斯法尔制药私人有限公司 2017-05-24 CN claimed
EP-2536733-A1 TRICYCLIC PYRIDINE DERIVATIVES, MEDICAMENTS CONTAINING SUCH COMPOUNDS, THEIR USE AND PROCESS FOR THEIR PREPARATION Boehringer Ingelheim International GmbH (DE) 2012-12-26 EP claimed
CN-102371718-A Decorative film and decorative device SIPIX CHEMICAL INC 2012-03-14 CN claimed
WO-2011101424-A1 TRICYCLIC PYRIDINE DERIVATIVES, MEDICAMENTS CONTAINING SUCH COMPOUNDS, THEIR USE AND PROCESS FOR THEIR PREPARATION BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-08-25 WO claimed
CN-1324027-C Naphthalenetetracarboxylic acid diimide derivatives and electrophotographic photoconductive material using the derivatives SAMSUNG ELECTRONICS CO LTD (KR) 2007-07-04 CN claimed
EP-0973791-A2 PROCESS FOR PREPARATION OF 7 ALPHA-CARBOXYL 9, 11-EPOXY STEROIDS AND INTERMEDIATES USEFUL THEREIN AND A GENERAL PROCESS FOR THE EPOXIDATION OF OLIFINIC DOUBLE BONDS G.D. Searle & Co. (US) 2000-01-26 EP claimed
WO-1997021720-A2 PROCESSES FOR PREPARATION OF 7 ALPHA-CARBOXYL 9,11-EPOXY STEROIDS AND INTERMEDIATES USEFUL THEREIN AND A GENERAL PROCESS FOR THE EPOXIDATION OF OLIFINIC DOUBLE BONDS G.D. SEARLE AND CO. (US) 1997-06-19 WO claimed
US-20230348441-A1 BICYCLIC COMPOUND THAT ACTS AS CRBN PROTEIN REGULATOR MEDSHINE DISCOVERY INC. (CN) 2023-11-02 US disclosed
CN-116589454-A Aromatic heterocyclic compound, preparation method and medical application thereof 中国医药研究开发中心有限公司 2023-08-15 CN disclosed
EP-3986392-A2 COMPOUNDS FOR TREATMENT OF PD-L1 DISEASES ChemoCentryx, Inc. (US) 2022-04-27 EP disclosed
CN-109503686-B Novel nucleoside phosphoramidate compounds and uses thereof 南京圣和药业股份有限公司 2022-03-11 CN disclosed
CN-108314697-B Novel nucleoside phosphoramidate compounds and uses thereof 南京圣和药业股份有限公司 2021-05-07 CN disclosed
CN-108546277-B Novel nucleoside phosphoramidate compounds and uses thereof 南京圣和药业股份有限公司 2021-05-07 CN disclosed
WO-1998025948-A9 PROCESSES FOR PREPARATION OF 9,11-EPOXY STEROIDS AND INTERMEDIATES USEFUL THEREIN 1998-11-19 WO disclosed
CN-1034807-C Bromate as inhibitor of nitrosamine formation for nitrate stabilized isothiazolones and process ROHM & HAAS (US) 1997-05-07 CN disclosed
CN-1131288-A Electronic photographic method MITA INDUSTRIAL CO LTD (JP) 1996-09-18 CN disclosed
CN-1131285-A Electrophotographic method using photosensitive material MITA INDUSTRIAL CO LTD (JP) 1996-09-18 CN disclosed
CN-1081436-A Method for synthesizing diphenyl sulfide tetracarboxylic acid and derivative CHANGCHUN APPLIED CHEMISTRY (CN) 1994-02-02 CN disclosed
CN-1071921-A Be used for suppressing to be formed the bromate and the method for nitrosamine by nitrate stabilized isothiazolones ROHM & HAAS (US) 1993-05-12 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230348441-A1 BICYCLIC COMPOUND THAT ACTS AS CRBN PROTEIN REGULATOR CRBN, CRKL, NCOR1 LMNA 3513/4885HTT 3097/4885MAPK1 873/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.